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ABSTRACT 
The Quinolones inhibit bacteria by 
interacting with DNA topoisomerases 
(gyrases) of which four subunits (two A 
and B monomers) have been identified 
thus, inhibiting bacterial DNA gyrase. 
High level resistance to quinolones can 
be produced by serial exposure of 
bacteria to subinhibitory concentration. 
A Total of 408 suspected UTI and high 
vagina swab (HVS) samples were 
examined for bacteria and the isolates 
obtained tested against the newer 
quinolones. Prevalence of Bacterial 
isolates revealed Escherichia coli 
110(92%) as the most isolated organism 
from urine, while Staphylococcus aureus 
31(32%) was the most isolated species 
from HVS samples. Bacterial species 
such as coliforms 55(70%) and Klebsiella 
spp 42(84%), equally had high prevalence 
rate in urine samples. Pseudomonas 
aeroginosa 19(66%) was next to 
Staphylococcus aureus in terms of 
prevalence of isolated strains from HVS 
samples.  The resistance pattern 
observed for these isolates, showed that 
the strains were least resistant to 
Ciprofloxacin, followed by Ofloxacin and 
Perfloxacin, while they were most 
resistant to Nalidixic acid. There was 
however no statistical significance 
(P<0.001) between the use of Ofloxacin 
and Perfloxacin, however, ANOVA 
showed a significant difference (P<0.05) 
between the pattern of Klebsiella spp 
resistance against Perfloxacin when 
compared to Proteus vulgaris. 
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INTRODUCTION 
The introduction of Nalixidic acid in 
1962, began the history of the newer 4-
quinolone antibacterial agents. The 
clinical significance of these drugs is 
based on their broad antibacterial 
spectrum, unique mechanism of action, 
good absorption from the gastro-
intestinal tract, excellent tissue distribution 
as well as low incidence of adverse 
reaction1. 
Recent studies indicate that the 
mechanism of action of these drugs is 
the inhibition of DNA topoisomerases 
(gyrases), thus inhibiting the bacterial 
DNA synthesis2,3. The drugs are 
bacteriocidal, with a single most 
bacteriocidal concentration and in 
greater or lesser concentrations, kill few 
bacteria.4. This Paradoxical effect of 
decreased killing at higher concentrations 
is most likely the result of dose- 
dependent inhibition of DNA synthesis5. 
Antimicrobial Activity: Nalixidic acid 
has greater antibacterial activity against 
Gram negative rods than Gram positive 
bacteria. It is active against most strains 
of Escherichia coli, Proteus mirabilis, 
Klebsiella spp and other Coliforms at 
concentrations easily achieved in the 
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urine i.e. 16pg/ml or lower 6 Gram 
positive organisms like Staphylococcus 
aureus, Streptococcus pneumonia and 
Streptococcus faecalis are resistant to 
Nalixidic acid.7 
Norfloxacin which is 100 times more 
active compared to Nalixidic acid, has a 
spectrum that includes entrococci, 
Staphylococci and Pseudomonas species.8  
It is active against most Gram positive 
and Gram negative bacteria implicated 
in UTI at concentrations easily attained 
in the urine. Norfloxacin is active against 
Haemophilus influenza, Neisseria gonorrhoea, 
regardless of beta-lactamase activity. 
However, it is less active against methicillin- 
resistant strains of Staphylococcus 
aureus. 9,10. 
Ciprofloxacin is said to be more 
potent than Norfloxacin, and is also 
active against most Gram positive and 
Gram negative infectious bacteria at 
concentrations easily attained in most 
tissues and body fluids.11. Ciprofloxacin 
has excellent activity against Chlamydia 
trachomatis and genital Mycoplasma, 
inhibiting 90% of isolates at 1ug/ml 
concentrations. 12, 13,14.  However, 
reduced susceptibility of these 
organisms to Ciprofloxacin occurs 
following serial exposure of the 
organisms to subinhibitory drug 
concentrations, this invariably may lead 
to cross resistance to other quinolones 
by the organisms14. 
Though, exact mechanism of 
bacterial resistance to the quinolones is 
unknown, it may occur when serine in 
position 83 of subunit A is replaced by 
trypophan 15. Or when inhibition of 
topoisomerase 1V interfere with replicated 
chromosomal DNA 16.  Finally, it could 
be due to a mutation in the gene coding 
for DNA gyrase or a mutation that alters 
the bacteria’s outer-membrane porins 17. 
In this work, we identified and 
assessed the prevalence of bacteria in 
UTI as well as determined the current 
trend in the resistance pattern of the 
bacteria isolates to the selected 
quinolones.  
MATERIALS AND METHODS 
Specimen: 
A total of 408 clinical specimens 
comprising of 305(75.25%) urine 
samples and 103(25.75%) of high 
vaginal swab (HVS) samples. All 
specimen were transported to the 
laboratory and were processed within 
2hours of collection. 
Isolation and identification: 
The specimens were innoculated 
onto Nutrient agar, Blood agar and 
MacConkey agar plates by streaking. 
Inoculated plates were then incubated 
aerobically at 37°C for 24 hours. After 
24 hours of incubation, discrete colonies 
were picked up and Gram stained and 
further subculturing was done to obtain 
pure cultures and biochemical tests 
carried out. 
Antimicrobial Susceptibility Testing 
This was done by the disc diffusion 
method. All isolates were subjected to 
testing using Nalidixic acid, Perfloxacin, 
Ciprofloxacin and Ofloxacin. 
Staphylococcus aureus, Oxford stain 
NCTC 6751 was used as control for 
Gram-positive organisms while Escherichia 
coli NCTC 10418 was used as control 
for Gram negative organisms. 
The results of the susceptibility test 
were interpreted as sensitive, 
intermediate or resistant, using the 
criteria below: 
A zone’s radius equal to or not more 
than 3mm smaller than the control was 
reported as sensitive. 
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A zone’s radius more than 3mm 
smaller than the control but not less 
than 3mm was reported as intermediate 
or moderate. 
A zone’s radius of 2mm or less (i.e., 
no zone of inhibition) was reported as 
resistant. 
RESULTS 
A total of 408 suspected UTI and 
vaginitis samples were analysed during 
this study. Of these samples 305(75.25%) 
were urine samples and 103(25.75%) 
were high vagina swab (HVS) samples. 
Males contributed 156(51.51%) of the 
urine samples while a total of 103(100 
*L) HVS samples were collected from 
females 18years and above. 
Table 1: Prevalence of Bacterial Strains Obtained From Urine and HVS Samples 
 
Bacterial Strains 
No of Isolates obtained from 






















Total 305(75.25%) 103(25.75%) 
 
 
Table 1.shows the prevalence of 
bacterial strains obtained from both 
urine and HVS samples. Escherichia 
coli has the highest prevalence among 
the bacterial isolates, with 119 samples. 
Of this total, 110(92%) were isolated 
from urine and 9(8%) was isolated from 
HVS samples. Staphylococcus aureus 
were isolated in 98 samples, 67(68%) 
from urine samples and 31(32%) from 
HVS samples. Klebsiella species were 
isolated were isolated from 50 samples 
42 from urine sample (84%) and 8 from 
HVS samples (16%). 
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Table 2: The Susceptibility Pattern of Bacterial Isolates and the Percentage (%) Resistance 
to the Selected Quinolones 
 
Bacterial Strains 
No (%) Resistance to the Quinolone 












































n = number of strains tested 
 
PEF = Perfloxacin 
CRP = Ciprofloxacin 
OFX = Ofloxacin 
NA = Nalixidic acid.
Table 2 shows the selected quinolones 
used and the isolates susceptibility 
pattern. Escherichia coli had 30 strains 
resistant to perfloxacin, 37 were 
resistant to Ciprofloxacin, 28 and 45 
isolates were resistant to Ofloxacin and 
Nalixidic acid. 
Nalixidic acid unarguably is the least 
sensitive of the selected quinolones, 
virtually all other bacterial isolates 
showed increased resistance to 
Nalidixic acid than the other selected 
quinolones. 
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In table 3, the minimum inhibitory 
concentration (MIC) in µg/ml of 
Escherichia coli to Nalixidic acid was 
observed to be 5.0µg/ ml, 0.059µg/ml to 
Perfloxacin, 0.250µg/ml and 0.125µg/ml 
to Ciprofloxacin and Ofloxacin respectively. 
Ofloxacin was observed to be a 
more potent for Staphylococcus aureus 
with the organisms having a MIC of 
0.039 to Ofloxacin, and 0.250µgml to 
both Perfloxacin and Ciprofloxacin 
respectively and 5.00µg/ml to Nalixidic 
acid. 
DISCUSSION 
The selected quinolones proved to 
be of chemotherapeutic value against 
the 408 samples analysed in the cause 
of this work. Some strains however were 
resistant. This work agrees with other 
similar works, especially with respect 
the incidence rates of Escherichia coli. 
Escherichia coli had earlier been 
reported as being the most prevalent 
organism implicated in UTI18. 
Escherichia coli was observed in this 
work to have 29.17% prevalent rate of 
24.02%. These prevalent rates makes 
Escherichia coli and Staphylococcus 
aureus the two most implicated 
organism in UTI , as well as the most 
prevalent Gram-negative and Gram-
positive organisms respectively. 
Nalixidic acid was seen to be the 
least potent of the selected quinolones. 
However, there is no statistical 
significance (p< 0.001) between the use 
of Ofloxacin and Perfloxacin in the 
treatment of the isolated strains. 
The pattern of Klebsiella spp 
resistance against Perfloxacin when 
compared to Proteus vulgaris was 
significant. In the same manner, the 
analysis of variance between the pattern 
of resistance against Perfloxacin shown 
by Pseudomonas aeruginosa compared 
to Proteus vulgaris was significant. 
 
CONCLUSION 
This study has been able to show 
that there is no real difference in 
therapeutic valve between the selected 
quinolones, safe for Nalixidic acid, which 
seen to have a wide range of resistance  
among the  isolated organisms. 
However, it is a first generation 
quinolone, compared to the other three 
which are second generation drugs. 
The study has also shown that 
Gram-negative organisms, especially 
Escherichia coli are predominantly 
responsible for UTI, and Staphylococcus 
aureus is the most prevalent Gram-
positive organisms implicated in UTI, 
although other Gram-positive organisms 
like Streptococcus species could be 
implicated. 
It is hoped that findings from this 
study would be of help in: 
Monitoring antimicrobial susceptibility, 
to ensure informed usage of antibiotics 
and usefulness of these drugs for longer 
period of time. 
Assist in effective management of 
UTI cases. 
Give a guide-line in choice of drug 
when certain related organisms are 
implicated in a UTI. 
REFERENCES 
1. Klepser MR (1999): Overview of the 
in vitro activity of the newer 
fluoroquinolones. Journal of infections 
Disease pharmacotherapy 4(2):1-12. 
2. Jawetz E (1998): Antimicrobial 
Chemotherapy In: Brooks GF, Butel 
JS, Morse SA, eds.  Medical 
Microbiology.21st ed. Stamford-
connecticut: Appleton and Lange, Pp 
173-175. 
3. Rybak MJ (1999): Mechanism of 
fluoroquinolone resistance and the 
role of topoisomerase activity. 
Journal of infectious Disease 
Pharmacotherapy 4(2): 13-20. 
Vol. 9 No. 1 December, 2007 Resistance pattern of urinary tract infection bacterial isolates to selected quinolones 
 
27
4. Crumplin GC (1987): Plasmid-
mediated resistance to Nalixidic acid 
and new 4-quinolones, Lancet (8): 
854-859. 
5. Smith JT, Lewin CS (1988): 
Chemistry and mechanisms of action 
of the quinolone antibacterials. In 
Andriole VT (ed): The Quinolones. 
London, Academic Press, pp 23- 81. 
6. Barlow AM (1963):  Nalixidic acid in 
infections of urinary tract. British 
Medical Journal (2): 1308-1311. 
7.  Lesher GY, Froclich EJ, Gruett MD 
(1962): 1,8-napthyridine derivatives. 
A new class of chemothera peutic 
agents. Journal of Medical Pharmacology 
Chemotherapy 2(5): 1063- 1069. 
8. Ito A. Hiria K, Inoue M, (1980): In 
vitro antibacterial activity of Am 7 5, 
a new nalidixic acid analog. 
Antimicrobial Agents Chemotherapy 
(17): 103-105. 
9. Neu HC, Labthavikul P (1982): In-
vitro activity of norfloxacin, a 
quinolone carboxylic acid, compared 
with that of β-lactams, aminoglycosides, 
and trimetoprim. Antimicrobial 
Agents Chemotherapy 911): 369-
374. 
10. Corrado ML, Chervbin CE, Shulman 
M (1989): The comparative activity of 
norfloxacin with other antimicrobial 
agents against Gram-positive and 
Gram-negative bacteria Journal of 
Antimicrobial Chemotherapy (11): 
369-372. 
11. Nicolau DP (1999): Establishing the 
clinical role of the new fluroquinolones. 
Journal of Infectious Disease Pharmaco-
therapy 4(2): 35-44. 
12. Hessen FWA, Myutjens HL (1984): 
In-vitro activities of ciprofloxacin, 
norfloxacin, pipemidic acid, cinoxacin 
and nalixidic acid against Chlamydia 
trachomatis. Antimicrobial Agents 
Chemotherapy (24):123-129). 
13.  Wolfson JS, Hopper DC (1985): The 
fluoroquinolones: structure, mechanism 
of action and resistance and 
resistance and spectra of activity in-vitro. 
Antimicrobial Agents Chemotherapy 
(28): 581-586. 
14. Norris S, Mandell CL (1988): The 
Quinolones: History and Overview. 
In Andriole VT (ed): The Qui 
nolones. London.   Academics 
Press, pp 290-314. 
15. Hirai K, Sazue S, Irikura T. (1987): 
Mutations producing resistance to 
norfloxacin in Pseudomonas aeruginosa. 
Antimicrobial Agents Chemotherapy 
(31): 582-585. 
16. Pan XS, Fisher M. (1996): Cloning 
and characteristics of the par C and par 
genes of Streptococus pneumoniae 
encoding DNA topoisomerase IV: 
Role in fluoroquinolone resistance. 
Journal of Bacteriology (178): 4060-
4062. 
17. Chapman JS, Bertasso A, 
Georgopapadakuo N H (1989): 
Fleroxacin resistance in Escherichia 
coli Antimicrobial Agents Chemotherapy 
(33): 239-244. 
18. Davidson S (2006): Disease due to 
infection In: Nicholas B, Nicki RC, 
Brain RW, eds. Principles and 
practice of Medicine 20th ed. New 
York: Churchill Livingstone, pp 467-
468. 
